Dimerix Ltd has released a press release.
DMX-200 tablet manufacture and human study timeline
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Dimerix
- Positive Results from Phase 2a Trial of DMX-200
- Research Validates Relevance of DMX Receptor-HIT Technology
- Investor Update
- Receipt of $420k Research & Development Tax Refund
- Corporate Presentation
Later from Dimerix
- Notice of Annual General Meeting/Proxy Form
- Dimerix Receives $545k R&D Tax Refund
- Ethics Committee Approval for Pharmacokinetic Trial
- Dimerix Phase 2a Subgroup Analysis Results
- Suspension from Official Quotation
Follow Dimerix into a list and get an email when it puts out news.
Follow Dimerix